Inventor · San Diego, CA, US

Nick Knudsen

38Patents
14h-index
60Co-inventors
80Inventor score

Filing activity: Dec 21, 2005 → Mar 3, 2022

Most-cited inventions

PatentTitleAreaCited byStatus
US8012931B2 Modified FGF-21 polypeptides and their uses Emerging Cross-Sectional Technologies 65 Active
US8383365B2 Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives Emerging Cross-Sectional Technologies 48 Active
US8735539B2 Relaxin polypeptides comprising non-naturally encoded amino acids Emerging Cross-Sectional Technologies 34 Active
US8178108B2 Methods for expression and purification of recombinant human growth hormone Human Necessities 29 Active
US8329869B2 Modified interferon beta polypeptides and their uses Human Necessities 21 Active
US7959926B2 Methods for expression and purification of recombinant human growth hormone mutants Human Necessities 21 Active
US7947473B2 Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid Human Necessities 19 Active
US8093356B2 Pegylated human interferon polypeptides Human Necessities 19 Active
US8114630B2 Modified interferon beta polypeptides and their uses Human Necessities 18 Active
US9079971B2 Modified FGF-21 polypeptides comprising non-naturally occurring amino acids Emerging Cross-Sectional Technologies 18 Active
US8080391B2 Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer Human Necessities 17 Expired
US9517273B2 Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids Emerging Cross-Sectional Technologies 16 Active
US9452222B2 Nucleic acids encoding modified relaxin polypeptides Emerging Cross-Sectional Technologies 15 Active
US9567386B2 Therapeutic uses of modified relaxin polypeptides Human Necessities 15 Active
US9975936B2 Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids Emerging Cross-Sectional Technologies 12 Active
US10253083B2 Therapeutic uses of modified relaxin polypeptides Human Necessities 10 Active
US9962450B2 Method of treating heart failure with modified relaxin polypeptides Emerging Cross-Sectional Technologies 10 Active
US10550190B2 Phosphate based linkers for intracellular delivery of drug conjugates Chemistry; Metallurgy 8 Active
US10702588B2 Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain Emerging Cross-Sectional Technologies 8 Active
US10751391B2 Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid Human Necessities 7 Active
US9938333B2 Modified leptin polypeptides and their uses Human Necessities 2 Active
US10377805B2 Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses Emerging Cross-Sectional Technologies 2 Active
US10800856B2 Prostate-specific membrane antigen antibody drug conjugates Chemistry; Metallurgy 2 Active
US8946148B2 Modified insulin polypeptides and their uses Human Necessities 2 Active
US10138283B2 Modified bovine G-CSF polypeptides and their uses Human Necessities 1 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.